April 28, 2022

Novocure Reports First Quarter 2022 Financial Results

Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend… Read More
learn more
April 19, 2022

Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu

Governor Sununu and Novocure leadership delivered keynote remarks, celebrating the construction of Novocure’s new flagship facility in Portsmouth, NH ST. HELIER, Jersey–(BUSINESS WIRE)–Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown… Read More
learn more
April 8, 2022

Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentations spans… Read More
learn more
April 1, 2022

Novocure to Report First Quarter 2022 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended… Read More
learn more